Executives On The Move: C4 Therapeutics Appoints A CMO, Innovio Pharma Brings In A COO, And A Departure At The Top For Sandoz
Targeted protein degradation company C4 Therapeutics welcomes former Novartis development leader as its CMO and immunotherapy technology firm Innovio hires a COO. At Sandoz, the chief executive departs.
You may also be interested in...
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
Executives On The Move: Comings And Goings At JSC Olainfarm And MorphoSys, Plus A Promotion At Twist Bioscience
Latvian pharma producer JSC Olainfarm picks next CEO and chairman, and CSO is scheduled to depart German therapeutic antibody company MorphoSys. Meanwhile, synthetic DNA manufacturer Twist Bioscience promotes SVP to chief commercial officer.
Executives On The Move: A Finance And Development Change At EyePoint Pharma And Exits At PPD And Novartis
Ophthalmology biopharma EyePoint Pharmaceuticals confirms its new CFO and head of corporate development. A former PPD med director is now CMO of vaccine developer ILiAD Biotechnologies and neurological disorders firm Ovid Therapeutics adds ex-Novartis VP as chief commercial officer.